cDNA Microarray Analysis of Differential Gene Expression in Gastric Cancer Cells Sensitive and Resistant to 5-Fluorouracil and Cisplatin
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Purpose: Gastric cancer is one of the most prevalent cancers worldwide. 5-fluorouracil (5-FU) and cisplatin are the most commonly used drugs for the treatment of gastric cancer. However, a significant number of tumors often fail to respond to chemotherapy. Materials and Methods: To better understand the molecular mechanisms underlying drug resistance in gastric cancer the gene expression in gastric cancer cells, which were either sensitive or resistant to 5-FU and cisplatin, were examined using cDNA microarray analysis. To confirm the differential gene expression, as determined using the microarray, semiquantitative RT-PCR was performed on a subset of differentially expressed cDNAs. Results: 69 and 45 genes, which were either up-regulated (9 and 22 genes) or down-regulated (60 and 25 genes), were identified in 5-FU- and cisplatin-resistant cells, respectively. Several genes, such as adaptor-related protein complex 1 and baculoviral IAP repeat-containing 3, were up-regulated in both drug-resistant cell types. Several genes, such as the ras homolog gene family, tropomyosin, tumor rejection antigen, protein disulfide isomerase-related protein, melanocortin 1 receptor, defensin, cyclophilin B, dual specificity phosphatase 8 and hepatocyte nuclear factor 3, were down-regulated in both drug- resistant cell types. Conclusion: These findings show that cDNA microarray analysis can be used to obtain gene expression profiles that reflect the effect of anticancer drugs on gastric cancer cells. Such data may lead to the assigning of signature expression profiles of drug-resistant tumors, which may help predict responses to drugs and assist in the design of tailored therapeutic regimens to overcome drug resistance.
참고문헌 (23)
- "Epidemiology of gastric cancer", 23, pp.281~91 (1996)
- "P-glycoprotein andmutidrug resistance", 6, pp.610~7 (1996)
- "Biology of the multidrug resistance-associated protein", pp.945~57 (1991)
- "DNA repair:enzymatic mechanisms andrelevance to drug response", 88, pp.346~60 (1996)
- "Use of a cDNA microarray to analyse gene expressionpatterns in human cancer", 14, pp.457~60 (1996)
- "Exploring the metabolic andgenetic control of gene expression on a genomic scale", 278, pp.680~6 (1997)
- "Drug target validation and identification ofsecondary drug target effects using DNA microarrays", 4, pp.1293~301 (1998)
- "The transcriptional program in the response of humanfibroblasts to serum", 283, pp.83~7 (1999)
- "The differential gene expression profiles between sensitive andresistant breast cancer cells to adriamycin by c DNA microarray", 36, pp.43~9 (2004)
- "Establishmentand characterization of 5-fluorouracil-resistant gastriccancer cells.", 159, pp.95~101 (2000)
- "Differential gene expression in retinoic acid-induced differentiation of acute promyelocyteic leukemia cells, NB4 and HL-60cells", 296, pp.1125~33 (2002)
- "Inhibitor of apoptosisproteins and their relatives: IAPs and other BIRPs", 2, pp.3009~ (2001)
- "Reciprocal downregulationof p53 and SOD2 gene expression: implication inp53 mediated apoptosis.", 20, pp.430~9 (2001)
- "Molecular and pharmacological properties of inwardly rectifyingK+ channels of human lung cancer cells", 435, pp.125~33 (2002)
- "Overexpression of theG-protein inwardly rectifying potassium channel 1 (GIRK1) inprimary breast carcinomas correlates with axillary lymph nodemetastasis.", 61, pp.582~8 (2001)
- "M-LDH serves as a sarcolemmal K(ATP)channel subunit essential for cell protection against ischemia.", 21, pp.3936~48 (2002)
- "Cytochrome p450 CYP1B1 protein expression:a novel mechanism of anticancer drug resistance", 62, pp.207~12 (2001)
- "Increasedexpression of cytochrome p450 1A1 and 1B1 genes in antiestrogen-resistant human breast cancer cell lines", 88, pp.902~6 (2000)
- "Platinum resistance. Experimental andclinical status.", pp.411~29 (1994)
- "Characterization of resistancemechanisms to cis-diamminedichloroplatinum in threesublines of the CC531 colon adenocarcinoma cell line in vitro", pp.487~93 (1994)
- "Using mRNA expression profiling to determine anticancerdrug efficacy", 47, pp.66~71 (2002)
- "Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNAmicroarray", 60, pp.4161~6 (2000)
- "cDNA microarray analysis of multidrugresistance:doxorubicin selection produces multiple defects inapoptosis signaling pathways", 99, pp.34~41 (2001)